Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial

AIMS/HYPOTHESIS: In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death) with ertugliflozin compared with placebo as 0.81 (0.63, 1.04). The effe...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Diabetologia
Glavni autori: Cherney, David Z. I., Charbonnel, Bernard, Cosentino, Francesco, Dagogo-Jack, Samuel, McGuire, Darren K., Pratley, Richard, Shih, Weichung J., Frederich, Robert, Maldonado, Mario, Pong, Annpey, Cannon, Christopher P.
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8099851/
https://ncbi.nlm.nih.gov/pubmed/33665685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-021-05407-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items